3 withdrawn, 2 completed, 2 unknown, 1 recruiting. 5 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Withdrawn 3, Terminated 1, Unknown 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow galactomannan: new trials by email Literature Review of galactomannan trials Research Report on galactomannan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M Prolectin-M - COVID-19, SARS CoV 2 Infection | Phase 2 | Unknown | Bioxytran Inc. | 40 | 2023-09-01 | 2023-09-28 |
| The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG, Prebiotics with galactomannan and oligofructose - Prader-Willi Syndrome | Not applicable | Recruiting | Children's Hospital of Fudan University | 60 | 2023-04-01 | 2026-07-06 |
| PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19 Galactomannan, PLACEBO - COVID-19, COVID-19 Pandemic | Phase 3 | Unknown | Bioxytran Inc. | 408 | 2022-04-01 | 2022-03-09 |
| Effect of Bacillus Coagulans and Galactomannans on Obese Patients Undergoing Sleeve Gastrectomy LactoWise®, Placebo - Obesity, Quality of Life | Not applicable | Completed | Loma Linda University | 60 | 2016-12-07 | 2021-09-24 |
| The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients PAZ320, Placebo - Type II Diabetes | Phase 2 | Withdrawn | Boston Therapeutics | 2012-09-01 | 2020-09-29 | |
| A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer GM-CT-01, 5-Fluorouracil, Leukovorin, bevacizumab - Colorectal Cancer | Phase 2 | Withdrawn | Galectin Therapeutics Inc. | 2006-10-01 | 2018-02-14 | |
| Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer GM-CT-01, 5-Fluorouracil - Cancer of the Bile Duct, Gallbladder Cancer | Phase 2 | Withdrawn | Galectin Therapeutics Inc. | 2006-09-01 | 2017-08-01 | |
| GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer GM-CT-01 plus 5-Fluorouracil - Colorectal Cancer | Phase 2 | Terminated | Galectin Therapeutics Inc. | 20 | 2005-05-01 | 2012-03-06 |
| Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors GM-CT-01, 5-fluorouracil - Colorectal Cancer, Lung Cancer | Phase 1 | Completed | Galectin Therapeutics Inc. | 40 | 2003-02-01 | 2012-03-12 |
Colorectal Neoplasms (3) · COVID-19 (2) · Neoplasms (2) · Bile Duct Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Cytokine Release Syndrome (1) · Diabetes Mellitus, Type 2 (1) · Gallbladder Neoplasms (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Obesity (1)
Galectin Therapeutics Inc. (4) · Bioxytran Inc. (2) · Boston Therapeutics (1) · Children's Hospital of Fudan University (1) · Loma Linda University (1)
United States (4) · Israel (2) · China (1) · France (1)
Keith Scharf, DO FACS (1) · Marilyn C Pike, M.D., Ph.D. (1) · Sunitha Mali (1) · Wei Lu, Dr (1)